Atea Pharmaceuticals (AVIR) vs Rezolute (RZLT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Atea Pharmaceuticals (AVIR) has outperformed Rezolute (RZLT) over the past year, gaining 64.5% versus a loss of 44.8%. Over five years, RZLT leads with a -26.8% price change compared with -86.9% for AVIR. Rezolute is the larger company by market cap ($471.0 million vs $413.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVIR | RZLT |
|---|---|---|
| Share price | $5.15 | $4.87 |
| Market cap | $413.05M | $471.04M |
| 1-day change | -0.10% | +4.96% |
| YTD return | +44.26% | +106.36% |
| 1-year return | +64.54% | -44.85% |
| 5-year return | -86.89% | -26.77% |
| EPS (TTM) | $-2.09 | $-0.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.45 | $11.46 |
| 52-week low | $2.87 | $1.07 |
| Distance from 52-week high | -20.16% | -57.49% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +82.91% | +101.23% |
| Average volume | 298.98K | 1.50M |
| Shares outstanding | 80.20M | 96.72M |
| Employees | 55 | 58 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AVIR has outperformed RZLT by 109.4 percentage points over the past year.
About Atea Pharmaceuticals
AVIR stock →Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
About Rezolute
RZLT stock →Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
AVIR vs RZLT FAQ
Which is bigger, Atea Pharmaceuticals or Rezolute?
Rezolute (RZLT) is larger, with a market capitalization of $471.04M compared with $413.05M for Atea Pharmaceuticals (AVIR).
Which stock has performed better over the past year, AVIR or RZLT?
AVIR returned +64.54% over the past 12 months, compared with -44.85% for RZLT (price return, excluding dividends). Past performance does not predict future results.
Are Atea Pharmaceuticals and Rezolute in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.